Extended Data Fig. 4: Shrinkage of metastatic lesions throughout the body after IMA203 application.

Lesion shrinkage under IMA203 treatment in different locations throughout the body. a) Best percent change in diameter of target lesions from baseline of all measured target lesions (one to five per patient) in IMA203 monotherapy population (n=21 in lung, n=31 in liver, n=10 in pleura, n=6 in abdomen/peritoneum, n=5 in skin, n=21 in lymph node and n=31 in other); ‘Other’ includes the following non-exhaustive list of organs: adrenal gland, bladder, kidney, spleen, pelvis, bone, brain and muscle. Box plots represent box bounds as the first and third quartiles, with horizontal lines inside the boxes depicting the median. Whiskers reach the minimum and maximum value of the data and each point represents the best change of one individual target lesion. Colors indicate the BOR according to RECIST 1.1 of the patient. b) Case study: CT scan and target lesion measurement (baseline and post-treatment) of patient 38 (DL5; cutaneous melanoma, post-baseline scan ~9 months post-T-cell infusion), patient 34 (DL5; uveal melanoma, post baseline scan ~12 months post-T-cell infusion), and patient 14 (DL2; synovial sarcoma, post-baseline scan ~24 months post-T-cell infusion). Red circles mark target lesion and green circles mark non-target lesion. BL: baseline; BOR: best overall response; cPR: confirmed partial response; PD: progressive disease; PR: partial response; RECIST: Response Evaluation Criteria in Solid Tumors; SD: stable disease.